Erasca, Inc. (ERAS)
16.37
-0.39
(-2.33%)
USD |
NASDAQ |
Sep 02, 16:00
16.31
-0.06
(-0.37%)
Pre-Market: 08:11
Erasca Research and Development Expense (TTM) : 108.88M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 108.88M |
| March 31, 2026 | 94.15M |
| December 31, 2025 | 92.85M |
| September 30, 2025 | 95.74M |
| June 30, 2025 | 100.89M |
| March 31, 2025 | 112.75M |
| December 31, 2024 | 115.36M |
| September 30, 2024 | 114.04M |
| June 30, 2024 | 111.62M |
| March 31, 2024 | 104.81M |
| December 31, 2023 | 103.82M |
| September 30, 2023 | 208.37M |
| Date | Value |
|---|---|
| June 30, 2023 | 211.34M |
| March 31, 2023 | 212.61M |
| December 31, 2022 | 214.46M |
| September 30, 2022 | 109.23M |
| June 30, 2022 | 102.68M |
| March 31, 2022 | 98.27M |
| December 31, 2021 | 84.77M |
| September 30, 2021 | 124.71M |
| June 30, 2021 | 112.22M |
| March 31, 2021 | 95.00M |
| December 31, 2020 | 101.30M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Revolution Medicines, Inc. | 1.287B |
| Tango Therapeutics, Inc. | 131.73M |
| Cogent Biosciences, Inc. | 285.88M |
| Apogee Therapeutics, Inc. | 240.59M |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |